BR0316973A - Uso de ácido docosahexanóico como substância ativa para o tratamento de lipodistrofia - Google Patents

Uso de ácido docosahexanóico como substância ativa para o tratamento de lipodistrofia

Info

Publication number
BR0316973A
BR0316973A BR0316973-1A BR0316973A BR0316973A BR 0316973 A BR0316973 A BR 0316973A BR 0316973 A BR0316973 A BR 0316973A BR 0316973 A BR0316973 A BR 0316973A
Authority
BR
Brazil
Prior art keywords
lipodystrophy
treatment
active substance
docosahexanoic acid
docosahexanoic
Prior art date
Application number
BR0316973-1A
Other languages
English (en)
Inventor
Juan Carlos Domingo Pedrol
Pere Domingo Pedrol
Original Assignee
Proyecto Empresarial Brudy Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Empresarial Brudy Sl filed Critical Proyecto Empresarial Brudy Sl
Publication of BR0316973A publication Critical patent/BR0316973A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"USO DE áCIDO DOCOSAHEXANóICO COMO SUBSTâNCIA ATIVA PARA O TRATAMENTO DE LIPODISTROFIA". A presente invenção refere-se ao uso de um extrato produzido de origem animal, vegetal ou microorganismo que compreende o ácido docosahexanóico como substância ativa para a fabricação de um medicamento para o tratamento de lipodistrofia em um mamífero. O dito tratamento é eficaz e supera as desvantagens de tratamentos correntes para lipodistrofia em pacientes infectados com HIV.
BR0316973-1A 2002-12-05 2003-12-01 Uso de ácido docosahexanóico como substância ativa para o tratamento de lipodistrofia BR0316973A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200202963A ES2209658B1 (es) 2002-12-05 2002-12-05 Utilizacion del acido docosahexaenoico como principio activo para el tratamiento de la lipodistrofia.
PCT/IB2003/005673 WO2004050077A1 (en) 2002-12-05 2003-12-01 Use of docosahexanoic acid as active substance for the treatment of lipodystrophy

Publications (1)

Publication Number Publication Date
BR0316973A true BR0316973A (pt) 2005-10-25

Family

ID=32405973

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316973-1A BR0316973A (pt) 2002-12-05 2003-12-01 Uso de ácido docosahexanóico como substância ativa para o tratamento de lipodistrofia

Country Status (24)

Country Link
US (1) US8202906B2 (pt)
EP (1) EP1585513B1 (pt)
JP (1) JP2006511514A (pt)
KR (1) KR100906086B1 (pt)
CN (1) CN100355421C (pt)
AT (1) ATE326959T1 (pt)
AU (1) AU2003302679B2 (pt)
BR (1) BR0316973A (pt)
CA (1) CA2506993C (pt)
CY (1) CY1105205T1 (pt)
DE (1) DE60305534T2 (pt)
DK (1) DK1585513T3 (pt)
EA (1) EA009711B1 (pt)
ES (2) ES2209658B1 (pt)
IL (1) IL168766A (pt)
IS (1) IS2384B (pt)
MX (1) MXPA05005911A (pt)
NO (1) NO20052960L (pt)
NZ (1) NZ540262A (pt)
PL (1) PL377563A1 (pt)
PT (1) PT1585513E (pt)
UA (1) UA79650C2 (pt)
WO (1) WO2004050077A1 (pt)
ZA (1) ZA200503872B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1656934A1 (en) * 2004-11-12 2006-05-17 Cognis IP Management GmbH Use of physiologically active fatty acids for treating lipodystrophy
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
JP5207342B2 (ja) * 2007-02-26 2013-06-12 独立行政法人産業技術総合研究所 炎症性サイトカイン産生抑制剤
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
SG10201408158SA (en) 2008-01-03 2015-03-30 Univ Aix Marseille Composition and methods used during anti-hiv treatment
CN110339187B (zh) * 2019-07-30 2021-12-14 中国医学科学院病原生物学研究所 缓解寨卡病毒感染相关的新生儿小头症的药物
CN116585216A (zh) * 2022-05-16 2023-08-15 上海中翊日化有限公司 一种含有羟基频哪酮视黄酸酯(hpr)并降低光损伤及炎症的抗衰组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3901048A1 (de) * 1989-01-14 1990-07-19 Chimicasa Gmbh Antikachectikum
US5089268A (en) * 1990-05-02 1992-02-18 Katz David P Egg phosphatide lipid emulsions altered for a specific therapeutic fatty acid composition
DE4017979A1 (de) * 1990-06-05 1991-12-12 Meyer Lucas Gmbh & Co Lipid- bzw. phospholipid-zusammensetzungen sowie diese enthaltendes mittel zur behandlung von erkrankungen sowie auf die zellmembrane zurueckzufuehrende stoerungen
JP3092180B2 (ja) * 1991-02-27 2000-09-25 日本油脂株式会社 低密度リポ蛋白受容体活性化剤
GB9116054D0 (en) * 1991-07-24 1991-09-11 Efamol Holdings Preparation of fatty acid medicaments
JPH0923817A (ja) * 1995-07-07 1997-01-28 Nisshin Oil Mills Ltd:The 油脂含有飲食物
FR2749133A1 (fr) 1996-06-04 1997-12-05 Pierre Moreau Obtention d'oeufs specifiquement enrichis en acide cervonique (acide docosahexaenoique ou dha). applications alimentaires, therapeutiques et industrielles de ces oeufs et de leurs extraits lipidiques
FR2790758A1 (fr) * 1999-03-09 2000-09-15 Commissariat Energie Atomique Solubilisation d'acides gras polyinsatures et de leurs derives par formation de complexes d'inclusion avec une cyclodextrine et leur utilisation dans des compositions pharmaceutiques, cosmetiques ou alimentaires
CA2290885A1 (fr) * 1999-12-02 2001-06-02 Universite De Sherbrooke Methode pour la transformation des tissus du loup marin
ATE384518T1 (de) * 2000-01-31 2008-02-15 Haerting S A Zusammensetzungen enthaltend phytosterol- und policosanolester von fettsäuren zur herabsetzung des cholesterol- und triglyceridspiegels
JP2001314170A (ja) * 2000-05-09 2001-11-13 Toyo Shinyaku:Kk 麦若葉由来の素材を含む抗コレステロール食品
ES2246769T3 (es) * 2000-05-22 2006-03-01 Pro Aparts - Investimentos E Consultoria Lda Composicion de acidos grasos que contiene al menos 80% en peso de epa y dha o sus derivados y su uso farmaceutico.
US8017651B2 (en) * 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia

Also Published As

Publication number Publication date
DE60305534T2 (de) 2007-05-16
JP2006511514A (ja) 2006-04-06
KR100906086B1 (ko) 2009-07-06
US8202906B2 (en) 2012-06-19
UA79650C2 (en) 2007-07-10
IS2384B (is) 2008-07-15
DK1585513T3 (da) 2006-09-18
WO2004050077A1 (en) 2004-06-17
ES2209658B1 (es) 2005-10-01
IS7912A (is) 2005-06-23
PT1585513E (pt) 2006-10-31
CA2506993C (en) 2010-04-13
AU2003302679B2 (en) 2009-01-15
CA2506993A1 (en) 2004-06-17
DE60305534D1 (de) 2006-06-29
MXPA05005911A (es) 2005-08-29
ES2265607T3 (es) 2007-02-16
KR20050085313A (ko) 2005-08-29
PL377563A1 (pl) 2006-02-06
CN100355421C (zh) 2007-12-19
EA009711B1 (ru) 2008-02-28
ES2209658A1 (es) 2004-06-16
US20060178436A1 (en) 2006-08-10
ZA200503872B (en) 2006-08-30
CY1105205T1 (el) 2010-03-03
IL168766A (en) 2009-11-18
EA200500765A1 (ru) 2005-12-29
NO20052960L (no) 2005-06-16
EP1585513A1 (en) 2005-10-19
NZ540262A (en) 2006-11-30
EP1585513B1 (en) 2006-05-24
ATE326959T1 (de) 2006-06-15
CN1720039A (zh) 2006-01-11
AU2003302679A1 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
Kumar et al. Emerging trends of herbal care in dentistry
Halder et al. Clove oil reverses learning and memory deficits in scopolamine-treated mice
BR0011116A (pt) Usos de uma nsaid que libera no como um sal farmaceuticamente aceitável ou um enanciÈmero do mesmo, e de uma nsaid que libera no e de um inibidor de bomba de próton suscetìvel a ácido ou um sal do mesmo ou um enanciÈmero ou de um sal do enanciÈmero, método para o tratamento de uma infecção bacteriana, e, formulação farmacêutica adequada para uso no tratamento de infecções bacterianas
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
ATE515253T1 (de) Zusammensetzungen auf basis von etyllinoleat und triethylcitrat zur behandlung von seborrhöe und akne
EP1852114A4 (en) COMPOSITION WITH DIHOMO (GAMMA) LINE ACIDIC ACID (DGLA) AS AN ACTIVE INGREDIENTS
BR0014262A (pt) Preparação antioxidante com base em extratos vegetais para o tratamento de problemas de adiposidade e circulatórios
WO2002015844A3 (en) Antimicrobial composition and methods of use in the treatment of disease
FI862609A0 (fi) Akne motverkande produkt.
SE0950392L (sv) Sammansättning för behandling av hudåkommor
HUP0304077A2 (hu) A bőr öregedése elleni gyógyászati és kozmetikai készítmények
DE60031016D1 (de) Verwendung von Antiseptika zur Herstellung von Arzneimitteln zur Prophylaxe und Behandlung von Entzündungen im Korperinneren des Menschen
MXPA05005911A (es) Utilizacion del acido docosahexaenoico como sustancia activa para el tratamiento de la lipodistrofia.
DE69927260D1 (de) Topische pharmazeutische zusammensetzung zur behandlung von haut- oder zirkulatorischen krankheiten auf inflammatorischer, immun-, proliferativer oder degenerativer basis
US7438937B2 (en) Topical burn composition containing Mentha haplocalyx and one or both of Aloe vera and recombinant human epidermal growth factor
US20150086529A1 (en) Therapeutic Burn Gel
BRPI0505988A (pt) formulação cosmética e/ou dermtólogica e uso da mesma
US20040185115A1 (en) Emu oil based methods and compositions for skin ailments
ITMI941680A1 (it) Estratto vegetale contro le ustioni
Ghorpade Nutty dermatitis‐marking‐nut dermatitis after use as a home remedy
Akaza et al. Control factor of cutaneous Propionibacterium acnes
Inoue et al. Functional identification of a vesicular ATP transporter, VNUT, mediating ATP release in human epidermal keratinocytes
CN104224669A (zh) 祛斑美白面膜
WO2004103073A1 (en) Emu oil based methods and compositions
BR0000098A (pt) Uso de um composto, subst ncia ou composição, na preparação de uma subst ncia ou composição, destinada a atuar como agente terapêutico ativo, remédio ou medicamento, no tratamento, entre outros males, de uma infecção viral em seres humanos ou animais; respectivos usos e processo de preparo e tratamento.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.